SCHEMBL3019142

SCHEMBL3019142

Cc1ccc(F)cc1S(=O)(=O)N1CCN(c2nc(Cc3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MAPT P10636 7/20 0.42
LMNA P02545 6/20 0.42
RAB9A P51151 2/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPK1 P28482 2/20 0.41
USP2 O75604 1/20 0.40
RECQL P46063 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TSHR P16473 2/20 0.39
TP53 P04637 2/20 0.39
THRB P10828 1/20 0.39
POLB P06746 1/20 0.38
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009882 0.93 CNR1 (0.42) ALDH1A1SMN1; SMN2L3MBTL1MAPTLMNA
SCHEMBL3005942 0.93 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2L3MBTL1MAPTLMNA
SCHEMBL3008281 0.93 SMN1; SMN2 (0.44) ALDH1A1SMN1; SMN2L3MBTL1MAPTLMNA
SCHEMBL3652689 0.92 MAPT (0.40) ALDH1A1SMN1; SMN2L3MBTL1MAPTLMNA
SCHEMBL3006735 0.92 CNR1 (0.43) ALDH1A1SMN1; SMN2L3MBTL1MAPTLMNA
SCHEMBL15671692 0.92 CNR1 (0.44) ALDH1A1SMN1; SMN2L3MBTL1MAPTLMNA
SCHEMBL3653659 0.91 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2L3MBTL1MAPTLMNA
SCHEMBL3009107 0.91 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2L3MBTL1MAPTLMNA
SCHEMBL3006749 0.91 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2L3MBTL1MAPTLMNA
SCHEMBL3020823 0.91 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2L3MBTL1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.